Autolus Therapeutics (NASDAQ:AUTL) Shares Down 2%

Autolus Therapeutics plc (NASDAQ:AUTL) was down 2% during mid-day trading on Monday . The company traded as low as $3.00 and last traded at $3.00. Approximately 7,013 shares traded hands during trading, a decline of 99% from the average daily volume of 570,760 shares. The stock had previously closed at $3.06.

Analysts Set New Price Targets

Separately, Truist Financial raised their target price on shares of Autolus Therapeutics from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, August 17th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics presently has a consensus rating of “Buy” and an average price target of $7.80.

Autolus Therapeutics Stock Performance

The company has a market cap of $529.73 million, a price-to-earnings ratio of -2.57 and a beta of 1.48. The stock’s fifty day simple moving average is $2.91 and its two-hundred day simple moving average is $2.48.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). Analysts predict that Autolus Therapeutics plc will post -0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently made changes to their positions in AUTL. Cetera Investment Advisers lifted its holdings in shares of Autolus Therapeutics by 8.3% during the 1st quarter. Cetera Investment Advisers now owns 124,300 shares of the company’s stock valued at $518,000 after acquiring an additional 9,550 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Autolus Therapeutics by 6.6% during the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock valued at $18,124,000 after acquiring an additional 268,818 shares in the last quarter. UBS Group AG lifted its holdings in shares of Autolus Therapeutics by 716.1% during the 1st quarter. UBS Group AG now owns 73,858 shares of the company’s stock valued at $308,000 after acquiring an additional 64,808 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Autolus Therapeutics by 144.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company’s stock valued at $1,566,000 after acquiring an additional 222,093 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Autolus Therapeutics during the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 64.78% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.